19997959

Source:http://linkedlifedata.com/resource/pubmed/id/19997959

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006826, umls-concept:C0013089, umls-concept:C0087111, umls-concept:C0205179, umls-concept:C0920321, umls-concept:C0964264
pubmed:issue	2
pubmed:dateCreated	2011-2-11
pubmed:abstractText	To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-30, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-31, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-31S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-32, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-32S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-33, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-33S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-33S2, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-34, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-34S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-34S2, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-35, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-35S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-36, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-36S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-36S2, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-37, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-37S1, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-37S2, http://linkedlifedata.com/resource/pubmed/grant/P30 CA014520-38
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-11283141, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-11595717, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-12829672, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-15315800, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-15388578, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-15627019, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-15867382, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-15990023, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-16146732, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-16481328, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-17112739, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-18760875, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-18977094, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-19121624, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-2845993, http://linkedlifedata.com/resource/pubmed/commentcorrection/19997959-7388791
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309330
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Metalloporphyrins, http://linkedlifedata.com/resource/pubmed/chemical/motexafin gadolinium
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1573-0646
pubmed:author	pubmed-author:AlbertiDonaD, pubmed-author:BaileyHoward HHH, pubmed-author:ModyTarak DTD, pubmed-author:RamanathanRamesh KRK, pubmed-author:ThomasJames PJP, pubmed-author:TraynorAnne MAM, pubmed-author:WildingGeorgeG
pubmed:issnType	Electronic
pubmed:volume	29
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	316-22
pubmed:dateRevised	2011-7-27
pubmed:meshHeading	pubmed-meshheading:19997959-Adult, pubmed-meshheading:19997959-Aged, pubmed-meshheading:19997959-Antineoplastic Agents, pubmed-meshheading:19997959-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19997959-Demography, pubmed-meshheading:19997959-Dose-Response Relationship, Drug, pubmed-meshheading:19997959-Doxorubicin, pubmed-meshheading:19997959-Female, pubmed-meshheading:19997959-Humans, pubmed-meshheading:19997959-Male, pubmed-meshheading:19997959-Metalloporphyrins, pubmed-meshheading:19997959-Middle Aged, pubmed-meshheading:19997959-Neoplasms, pubmed-meshheading:19997959-Treatment Outcome
pubmed:year	2011
pubmed:articleTitle	Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
pubmed:affiliation	University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI 53792, USA. amt@medicine.wisc.edu
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase I